Value through Innovation27 July 2016

Clinical Study Results

  • Bivatuzumab - Head and Neck Neoplasms
    Clinical Study Number 1170.1
    Study Indication Head and Neck Neoplasms
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    A phase I dose escalation study with 99m-TC -  or 186-Re-labelled humanised monoclonal antibody BIWA 4, in patients with head and neck cancer

    Study Document Trial synopsis 1170.1_CO english
  • Bivatuzumab - Breast Neoplasms
    Clinical Study Number 1170.2
    Study Indication Breast Neoplasms
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    A phase I biodistribution study with 186 Re-labelled humanised monoclonal antibody BIWA 4, in patients with adenocarcinoma of the breast.

    Study Document Trial synopsis 1170.2_CO english
  • Bivatuzumab - Carcinoma, Non-Small-Cell Lung
    Clinical Study Number 1170.3
    Study Indication Carcinoma, Non-Small-Cell Lung
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    A phase I biodistribution study with 186 Re-labelled humanised monoclonal antibody BIWA 4, in patients with non-small cell lung cancer.

    Study Document Trial synopsis 1170.3_CO english
  • Bivatuzumab - Breast Neoplasms
    Clinical Study Number 1191.1
    Study Indication Breast Neoplasms
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    An open phase I single dose escalation study of bivatuzumab mertansine administered intravenously in female patients with CD44v6 positive metastatic breast cancer with repeated administration in patients with clinical benefit

    Study Document Trial synopsis 1191.1 english
  • Bivatuzumab - Head and Neck Neoplasms
    Clinical Study Number 1191.2
    Study Indication Head and Neck Neoplasms
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    An open phase I single dose escalation study of bivatuzumab mertansine administered intravenously in patients with advanced squamous cell carcinoma of the head and neck with repeated administration in patients with clinical benefit

    Study Document Trial synopsis 1191.2 english
  • Bivatuzumab - Breast Neoplasms
    Clinical Study Number 1191.3
    Study Indication Breast Neoplasms
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    An open phase I dose escalation study of bivatuzumab mertansine administered intravenously once per week for three weeks in female patients with CD44v6 positive recurrent or metastatic breast cancer with repeated administration courses in patients with clinical benefit

    Study Document Trial synopsis 1191.3 english
  • Bivatuzumab - Head and Neck Neoplasms
    Clinical Study Number 1191.4
    Study Indication Head and Neck Neoplasms
    Product Bivatuzumab
    Generic Name Bivatuzumab
    Lab Code
    Clinical Phase I
    Study Title

    An open phase I dose escalation study of bivatuzumab mertansine administered intravenously once per week for three weeks in patients with advanced squamous cell carcinoma of the head and neck or esophagus with repeated administration courses in patients with clinical benefit

    Study Document Trial synopsis 1191.4_CO english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.